Breaking News

IBM No Longer Sees Delivering 'at Least $20 Operating EPS' in 2015
Tweet TWEET

SHIRE PLC: Dr. Jeff Jonas joins Shire Leadership Team

Dr. Jeff Jonas appointed President of Shire Regenerative Medicine Business and
joins Shire Leadership Team 
La Jolla, California, USA- November 15, 2012 - Shire plc (LSE: SHP, NASDAQ:
SHPG), announces that Jeff Jonas M.D. has been appointed President of Shire's
Regenerative Medicine (RM) business, effective November 15, 2012. Jeff will
report to Shire Chief Executive, Angus Russell, and will join the Shire
Leadership Team. 
After a varied career in research & development, commercial and entrepreneurial
business roles, Jeff joined Shire in July 2008 as leader of the Specialty
Pharmaceuticals (SP) Research & Development (R&D) team. 
Jeff has been closely involved with the RM business since Shire acquired it as
Advanced BioHealing in June 2011. In addition to his role as head of the SP R&D
team, Jeff has been leading the RM R&D team and has been a member of the RM
leadership team. Jeff will lead the newly established RM team to take the
business to its next stage of growth. 
Jeff's role as head of the SP R&D team will be filled by Arnaud Partiot M.D.
Arnaud is a qualified psychiatrist and has been a senior member of the Shire SP
team in various clinical research & development, medical affairs and commercial
roles since joining Shire in 2004. 
Kevin Rakin, who led Advanced BioHealing Inc. since 2007 and during its
integration into Shire, is stepping down from his position as Regenerative
Medicine President and from the Shire Leadership Team to pursue new career
interests. Kevin will be available to provide transitional support through 28
December 2012. 
Says Shire Chief Executive, Angus Russell: 
"We are pleased with the progress we are making in transforming our
Regenerative Medicine business. Jeff's insight and experience will enable us to
build on this as we shape this business for future growth. We have great
ambition for this business and we're committed to seeing those ambitions
realised." 
"I'd like to recognise Kevin Rakin as a leader of this business during its
integration into Shire; and we wish him well in his new endeavours. " 
Says Jeff Jonas: 
"Shire's Regenerative Medicine business has so much potential; it serves a
growing patient population with unmet needs and we have an excellent,
differentiated product in DERMAGRAFT, already commercialised for diabetic foot
ulcers. We're exploring other possible indications for DERMAGRAFT and we
believe we can expand its use into new geographies. The science and technology
in regenerative medicine is developing well and we see many opportunities to
acquire other exciting assets to build a robust and attractive pipeline.
Leading this business to greater heights is a very exciting opportunity for
me." 
Further background on Jeff Jonas 
Before joining Shire in 2008, he served as Executive Vice President at Isis
Pharmaceuticals in charge of clinical and pre-clinical development, regulatory
affairs, quality assurance and compliance, and had broad responsibility for the
product pipeline. 
Prior to this, Jeff was Chief Medical Officer and Executive Vice President at
Forest Laboratories, Inc. 
He began his career at Upjohn Laboratories where he advanced to the position of
Chief Medical Officer. 
Jeff has also been a successful entrepreneur. He founded and led AVAX
Technologies, a leader in autologous cell therapy and individualized therapy.
Dr. Jonas led AVAX through several successful financings, including an initial
public offering in 1997. 
In 2001, he co-founded SCEPTOR Industries, a biotechnology company involved in
biodefense surveillance. 
Jeff has published more than 70 scientific papers and chapters and has received
a number of awards. 
Jeff received his M.D. from Harvard Medical School and completed a residency in
psychiatry at Harvard. Shortly thereafter, he was appointed Chief Resident in
psychopharmacology at McLean Hospital, Harvard Medical School. 
For further information please contact: 
Investor Relations                                                              
                                                                           
Eric Rojas                              erojas@shire.com     +1 781 482 0999    
                                                                           
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157    
                                                                           
Media                                                                           
                                                                           
Jessica Mann (Corporate)                jmann@shire.com      +44 1256 894 280   
                                                                           
Gwen Fisher (Specialty Pharmaceuticals) gfisher@shire.com    +1 484 595 9836    
                                                                           
Lindsey Hart (Regenerative Medicine)    lhart@shire.com      +1 615 250 3311    
Notes to editors 
SHIRE PLC 
Shire enables people with life-altering conditions to lead better lives. 
Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of: 
* Behavioral Health and Gastro Intestinal conditions 


      * Rare Diseases
      * Regenerative Medicine
    as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.

For further information on Shire, please visit the Company's website:
www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995

Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, the Company's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of the Company's products; the Company's
ability to manufacture its products in sufficient quantities to meet demand;
the impact of competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other intellectual
property rights relating to its products; the Company's ability to obtain and
maintain government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.
                                                                              

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     


                                              
www.shire.com 
-0- Nov/15/2012 15:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.